Mettler-Toledo International Inc.
NYSE•MTD
CEO: Mr. Patrick K. Kaltenbach
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1997-11-14
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection equipment, x-ray systems, check weighing equipment, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of weighing and software solutions, AI-driven image recognition solution, and automated packaging and labelling solutions for the meat backroom. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.
Contact Information
Market Cap
$26.93B
P/E (TTM)
31.1
29.6
Dividend Yield
--
52W High
$1.53K
52W Low
$962.54
52W Range
Rank18Top 5.0%
6.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$1.13B+0.00%
4-Quarter Trend
EPS
$14.02+0.00%
4-Quarter Trend
FCF
$184.08M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Net Sales Growth Net sales reached $4.03B USD in 2025, increasing 4% in USD terms, despite soft end-market demand.
Strong Operating Cash Flow Cash provided by operating activities totaled $955.8M USD in 2025, supporting liquidity needs and capital expenditures.
Laboratory Segment Performance Laboratory products/services generated $2.24B USD, growing 3% in USD, driven by process analytics growth.
Sustained R&D Investment Research and development expenses were $199.4M USD in 2025, maintained at approximately 5.0% of net sales.
Risk Factors
Gross Margin Erosion Risk Gross profit margin fell to 59.4% in 2025, reflecting higher tariff costs and unfavorable business mix impacts.
China Concentration Exposure China represents 16% of sales; geopolitical tensions and local economic challenges create significant operational risks.
Cybersecurity Infrastructure Risk Reliance on technology infrastructure creates vulnerability to sophisticated cyber attacks, potentially causing service interruptions and data loss.
Currency Volatility Exposure Strengthening Swiss franc against USD/Euro reduces earnings; 1% change impacts tax-excluded earnings by $2.8M–$3.1M annually.
Outlook
Automation Digitalization Focus Expect continued benefit from market trends toward automation and digitalization, including customer replacement cycles into 2026.
Service Business Expansion Service business delivered strong results, expanding value-added offerings for uptime and regulatory compliance support globally.
Capital Allocation Strategy Board authorized additional $2.75B for share repurchases; $3.7B remaining availability as of year-end 2025.
Strategic Acquisition Focus Pursue "bolt-on" acquisitions leveraging global network, targeting life sciences and distribution channel expansion opportunities.
Peer Comparison
Revenue (TTM)
$129.66B
$16.31B
$13.95B
Gross Margin (Latest Quarter)
67.1%
67.0%
62.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ALC | $38.02B | 38.9 | 4.4% | 16.6% |
| A | $32.54B | 25.2 | 19.7% | 26.2% |
| IQV | $28.40B | 20.9 | 22.3% | 54.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
8.5%
Steady Growth
4Q Net Income CAGR
20.4%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 29, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data